[Summer Rewind] A New Method to Treat Colorectal Cancer

Did you miss these insights published this year? Now is the time to catch up. This summer, we offer you the opportunity to discover or rediscover the medical news published in our affiliated publication, DirectIndustry e-magazine. In this article, we explore a new method developed by French start-up Brenus Pharma to treat colorectal cancer.

French tech startup Brenus Pharma is making significant strides in cancer treatment. Colorectal cancer, a prevalent and deadly form of cancer affecting over 20 million people globally, has a five-year survival rate of less than 12% and ranks as the third leading cause of cancer mortality worldwide.

Traditionally, patients with colorectal cancer undergo highly toxic chemotherapy, emphasizing the need for more effective and less harmful treatment options. Brenus Pharma’s innovative approach leverages vaccine-based immunotherapies for cancer. By replicating the resistance mechanisms seen in patient tumor cells, the company trains the patient’s immune system to recognize these resistance signatures and destroy tumor cells as soon as they appear.

This cutting-edge strategy promises personalized and more effective treatments, offering hope for improved outcomes. As Brenus Pharma gains recognition and prepares for upcoming clinical trials, their groundbreaking work could revolutionize cancer therapy.

Explore the full article for more details: Brenus Pharma: Pioneering a New Method to Treat Colorectal Cancer